Rheumatology International

, Volume 36, Issue 2, pp 231–241 | Cite as

Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry

  • M. Cárdenas
  • S. de la Fuente
  • P. Font
  • M. C. Castro-Villegas
  • M. Romero-Gómez
  • D. Ruiz-Vílchez
  • J. Calvo-Gutiérez
  • A. Escudero-Contreras
  • M. A. Casado
  • J. R. Del Prado
  • E. Collantes-Estévez
Original Article - Health Services Research

Abstract

Biological drugs have proven efficacy and effectiveness in treatment of rheumatoid arthritis (RA), although none has been shown to be superior. Few studies have evaluated the cost-effectiveness of biological drugs in real-life clinical conditions. The objective of this study was to compare the cost-effectiveness of infliximab, etanercept and adalimumab in achieving clinical remission (DAS28 < 2.6) when used as initial biological therapy. Patients were diagnosed with RA who began treatment with infliximab, etanercept or adalimumab in the Reina Sofia Hospital (Cordoba, Spain) between January 1, 2007, and December 31, 2012. Effectiveness was measured as the percentage of patients who achieved clinical remission after 2 years. The cost analysis considered the use of direct health resources (perspective of the healthcare system). Cost-effectiveness was calculated by dividing the total mean cost of each treatment by the percentage of patients who achieved remission. One hundred and thirty patients were included: 55 with infliximab, 44 with adalimumab and 31 with etanercept. After 2 years, 45.2 % of patients with adalimumab achieved clinical remission, versus 29.1 % with infliximab (p = 0.133) and 22.7 % with etanercept (p = 0.040), with no differences between etanercept and infliximab (p = 0.475). The average total cost at 2 years was €29,858, €25,329 and €23,309 for adalimumab, infliximab and etanercept, respectively, while the mean cost (95 %CI) to achieve remission was €66,057 (48,038–84,076), €87,040 (78,496–95,584) and €102,683 (94,559–110,807), respectively. Adalimumab was more efficient than etanercept (p < 0.001) and infliximab (p = 0.026), with no differences between etanercept and infliximab (p = 0.086). Adalimumab was the most cost-effective treatment in achieving clinical remission in real-life clinical conditions in RA patients during the study period.

Keywords

Rheumatoid arthritis Biological drugs Cost-effectiveness Real-life clinical conditions 

References

  1. 1.
    Carmona L, Ballina J, Gabriel R, Laffon A (2001) The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60:1040–1045PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L (2008) The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology (Oxford) 47:1088–1092CrossRefGoogle Scholar
  4. 4.
    Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Rodríguez-Valverde V, Cáliz R, Álvaro JMA-G, de la Fuente JLM, Mulero-Mendoza J, Tornero-Molina J et al (2006) III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide. Reumatol Clin 2:S52–S59CrossRefPubMedGoogle Scholar
  6. 6.
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45 (Erratum in: Arthritis Rheum 48:855) CrossRefPubMedGoogle Scholar
  7. 7.
    Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG (2006) Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65:753–759PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C et al (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65:28–38PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH et al (2006) Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 33:854–861 (Epub 2006 Mar 15) PubMedGoogle Scholar
  10. 10.
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259CrossRefPubMedGoogle Scholar
  11. 11.
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–1939CrossRefPubMedGoogle Scholar
  12. 12.
    Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–1103PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37CrossRefPubMedGoogle Scholar
  14. 14.
    Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375–382CrossRefPubMedGoogle Scholar
  15. 15.
    St Clair EW, Van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443CrossRefPubMedGoogle Scholar
  16. 16.
    Resolución 2/05 de 25 de enero de 2005 del Servicio Andaluz de Salud sobre la creación de las Comisiones Asesoras para el Uso Racional de los Medicamentos utilizados en enfermedades reumáticas inflamatorias en el ámbito del Servicio Andaluz de Salud. Resolución SC 2/2005 (25-1) del SASGoogle Scholar
  17. 17.
    Agarwal SK (2011) Biological agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm 17:S14–S18PubMedGoogle Scholar
  18. 18.
    Ruiz-Montesinos MD, Hernández Cruz B, Ariza-Ariza R, Carmona L, Ballina J, Navarro-Sarabia F (2005) Cost analysis in a cohort of rheumatoid arthritis patients managed in rheumatology units in Spain. Reumatol Clin 1:193–199CrossRefPubMedGoogle Scholar
  19. 19.
    Malhan S, Pay S, Ataman S, Dalkilic E, Dinc A, Erken E et al (2012) The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. Clin Exp Rheumatol 30:202–207PubMedGoogle Scholar
  20. 20.
    Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A et al (2008) Incorporating considerations of resources use into grading recommendations. BMJ 336:1170–1173PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewé R et al (2010) Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:995–1003CrossRefPubMedGoogle Scholar
  22. 22.
    Carrasco M, Sulleiro S, Tejera M, Díaz M (2008) Estudio sobre la accesibilidad de los pacientes a los tratamientos biológicos de artritis reumatoide. ReES 8:6–46Google Scholar
  23. 23.
    Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ (2012) Annual cost of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ 15:264–275CrossRefPubMedGoogle Scholar
  24. 24.
    Gilbert TD, Smith D, Ollendorf DA (2004) Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 5:36PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M (2008) Retrospective claims data analysis adjustment patterns of TNF antagonist among patients with rheumatoid arthritis. Curr Med Res Opin 24:2229–2240CrossRefPubMedGoogle Scholar
  26. 26.
    Prevoo MLL, Van‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48CrossRefPubMedGoogle Scholar
  27. 27.
    Turchetti G, Scalone L, Della Casa AO, Mosca M, Montella S, Cortesi PA et al (2012) The rationale of pharmacoeconomic analysis in rheumatologic indications. Clin Exp Rheumatol 30:S64–S71PubMedGoogle Scholar
  28. 28.
    Rubio-Terrés C, Ordovás JP, Pla R, Martínez C, Sánchez MJ, Rosado MA (2007) Utilización y coste de los modificadores de la artritis reumatoide en España (estudio PRAXIS). Farm Hosp 31:78–92CrossRefPubMedGoogle Scholar
  29. 29.
    Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E, Trivato-López N, Herranz-Alonso A, Morell-Balandrón A (2013) Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clin Exp Rheumatol 31:559–565PubMedGoogle Scholar
  30. 30.
    González A, Gómez M, Borrás J, Giner EJ (2013) Adalimumab versus Etanercept en el tratamiento de la artritis reumatoide: análisis coste-efectividad. Farm Hosp 37:286–294Google Scholar
  31. 31.
    Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L et al (2009) Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, doble-blind study failed to confirm its efficacy. Ann Rheum Dis 68:1285–1289CrossRefPubMedGoogle Scholar
  32. 32.
    Smolen JS (2012) Treat-to-target: rationale and strategies. Clin Exp Rheumatol 30:S2–S6PubMedGoogle Scholar
  33. 33.
    Alehata D, Smolen JS (2011) Joint damage in rheumatoid arthritis progresses in remission according to the disease activity in 28 joints and is driven by residual swollen joints. Arthritis Rheum 63:3702–3711CrossRefGoogle Scholar
  34. 34.
    Smolen JS, Alehata D (2013) Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 72:3–6CrossRefPubMedGoogle Scholar
  35. 35.
    Schoels M, Smolen JS (2012) Treating rheumatoid arthritis to target: evidence-based recommendations for enhanced disease management. Reumatol Clin 8:1–2CrossRefPubMedGoogle Scholar
  36. 36.
    Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Moens HJB, Zijlstra TR et al (2013) Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskeletal Disord 14:350. doi:10.1186/1471-2474-14-350 CrossRefGoogle Scholar
  37. 37.
    Sokka T, Haugeberg G, Asikainen J, Widding HIJ, Kokko A, Rannio T et al (2013) Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. Clin Exp Rheumatol 31:409–414PubMedGoogle Scholar
  38. 38.
    Lundkvist J, Kastäng F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8:S49–S60CrossRefPubMedGoogle Scholar
  39. 39.
    Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223CrossRefPubMedGoogle Scholar
  40. 40.
    Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196CrossRefPubMedGoogle Scholar
  41. 41.
    Kobelt G, Jönsson B (2008) The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ 8:S95–S106CrossRefGoogle Scholar
  42. 42.
    Schoels M, Aletaha D, Smolen JS, Wong JB (2012) Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 71:1303–1308CrossRefPubMedGoogle Scholar
  43. 43.
    Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R et al (2010) Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 12:R42PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Rat AC, Boissier MC (2004) Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 71:518–524CrossRefPubMedGoogle Scholar
  45. 45.
    Burton W, Morrison A, Maclean R, Ruderman E (2006) Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 56:18–27CrossRefGoogle Scholar
  46. 46.
    Joyce GF, Goldman DP, Karaca-Mandic P, Lawless GD (2008) Impact of specialty drugs on the use of other medical services. Am J Manag Care 14:821–828PubMedCentralPubMedGoogle Scholar
  47. 47.
    Lacaille D, White MA, Backman CL, Gignac MA (2007) Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients’ perspective. Arthritis Rheum 57:1269–1279CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • M. Cárdenas
    • 1
    • 2
  • S. de la Fuente
    • 1
  • P. Font
    • 2
    • 3
    • 4
  • M. C. Castro-Villegas
    • 2
    • 3
    • 4
  • M. Romero-Gómez
    • 2
    • 3
    • 4
  • D. Ruiz-Vílchez
    • 2
    • 3
    • 4
  • J. Calvo-Gutiérez
    • 2
    • 3
    • 4
  • A. Escudero-Contreras
    • 2
    • 3
    • 4
  • M. A. Casado
    • 5
  • J. R. Del Prado
    • 1
  • E. Collantes-Estévez
    • 2
    • 3
    • 4
  1. 1.Pharmacy DepartmentReina Sofía Universitary HospitalCórdobaSpain
  2. 2.University of CórdobaCórdobaSpain
  3. 3.Rheumatology DepartmentReina Sofía Universitary HospitalCórdobaSpain
  4. 4.IMIBICCórdobaSpain
  5. 5.Pharmacoeconomics & Outcomes Research Iberica (PORIB)MadridSpain

Personalised recommendations